NASDAQ, RXII - Rxi Pharmaceuticals
We were incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on April 3,
2006, changed our name to RXi Pharmaceuticals Corporation on November 28, 2006,
and began operations as a majority-owned subsidiary of CytRx Corporation
(?CytRx?) in January 2007. We are a discovery-stage biopharmaceutical company
pursuing the development and potential commercialization of proprietary
therapeutics based on RNA interference (RNAi) for the treatment of human
diseases. We believe RNAi-based therapeutics have the potential to effectively
treat a broad array of diseases by interfering with (sometimes referred to as
silencing) the expression of targeted disease-associated genes. Our initial
focus is on the treatment of neurological diseases, metabolic diseases and
oncology.
RXi was founded by CytRx and four prominent researchers in the field of RNAi,
including Dr. ...
Read SEC Filing on NASDAQ.com »